Literature DB >> 33617594

Characteristics of sickle cell patients with frequent emergency department visits and hospitalizations.

Kyle Kidwell1,2, Camila Albo2, Michael Pope2, Latanya Bowman3, Hongyan Xu4, Leigh Wells3, Nadine Barrett3, Niren Patel3, Amy Allison5, Abdullah Kutlar3.   

Abstract

Vaso-occlusive episodes (VOEs) are a hallmark of sickle cell disease (SCD), and account for >90% of health care encounters for this patient population. The Cooperative Study of Sickle Cell Disease, a large study enrolling >3000 patients, showed that the majority of SCD patients (80%) experienced 0-3 major pain crises/year. Only a small minority (~5%) experienced ≥6 VOEs/year. Our study sought to further understand this difference in VOE frequency between SCD patients. We analyzed 25 patients (13M/12F, mean age of 28.8) with ≥6 ED visits or hospitalizations/year (high utilizers), and compared these with 9 patients (6M/3F, mean age of 37.6) who had ≤2 ED visits or hospitalizations/year (low utilizers). All subjects were given a demographic survey along with questionnaires for depression, anxiety, and Health Locus of Control. Each subject then underwent quantitative sensory testing (QST) with three different modalities: pressure pain sensitivity, heat and cold sensitivity, and Von Frey monofilament testing. Laboratory and clinical data were collected through subjects' medical records. CBC and chemistry analysis showed high utilizers had higher WBC (p<0.01), ANC (p<0.01), total bilirubin (p = 0.02), and lower MCV (p = 0.03). Opioid use (morphine equivalents) over the past 6 months was significantly higher in the high utilizer group (12125.7 mg vs 2423.1 mg, p = 0.005). QST results showed lower pressure pain threshold at the ulna (224.4 KPa vs 338.9 KPa, p = 0.04) in the high utilizer group. High utilizers also had higher anxiety (9.0 vs 4.6, p = 0.04) and depression scores (10.0 vs 6.0, p = 0.051). While the low utilizer group had higher education levels with more associate and bachelor degrees (p = 0.009), there was no difference in income or employment. These data show that many biological and psychosocial factors contribute to high health care utilization in SCD. A multi-disciplinary and multi-faceted approach will be required to address this complex problem.

Entities:  

Year:  2021        PMID: 33617594      PMCID: PMC7899345          DOI: 10.1371/journal.pone.0247324

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  20 in total

1.  Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.

Authors:  Martin H Steinberg; Franca Barton; Oswaldo Castro; Charles H Pegelow; Samir K Ballas; Abdullah Kutlar; Eugene Orringer; Rita Bellevue; Nancy Olivieri; James Eckman; Mala Varma; Gloria Ramirez; Brian Adler; Wally Smith; Timothy Carlos; Kenneth Ataga; Laura DeCastro; Carolyn Bigelow; Yogen Saunthararajah; Margaret Telfer; Elliott Vichinsky; Susan Claster; Susan Shurin; Kenneth Bridges; Myron Waclawiw; Duane Bonds; Michael Terrin
Journal:  JAMA       Date:  2003-04-02       Impact factor: 56.272

2.  Depression, quality of life, and medical resource utilization in sickle cell disease.

Authors:  Soheir S Adam; Charlene M Flahiff; Shital Kamble; Marilyn J Telen; Shelby D Reed; Laura M De Castro
Journal:  Blood Adv       Date:  2017-10-12

3.  Critical role of endothelial cell activation in hypoxia-induced vasoocclusion in transgenic sickle mice.

Authors:  John D Belcher; Hemchandra Mahaseth; Thomas E Welch; Asa E Vilback; Khalid M Sonbol; Venkatasubramaniam S Kalambur; Paul R Bowlin; John C Bischof; Robert P Hebbel; Gregory M Vercellotti
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-01-21       Impact factor: 4.733

4.  Association between elevated depressive symptoms and clinical disease severity in African-American adults with sickle cell disease.

Authors:  Brian Laurence; David George; Dexter Woods
Journal:  J Natl Med Assoc       Date:  2006-03       Impact factor: 1.798

5.  Pain in sickle cell disease. Rates and risk factors.

Authors:  O S Platt; B D Thorington; D J Brambilla; P F Milner; W F Rosse; E Vichinsky; T R Kinney
Journal:  N Engl J Med       Date:  1991-07-04       Impact factor: 91.245

6.  A brief measure for assessing generalized anxiety disorder: the GAD-7.

Authors:  Robert L Spitzer; Kurt Kroenke; Janet B W Williams; Bernd Löwe
Journal:  Arch Intern Med       Date:  2006-05-22

7.  Depression in sickle cell disease.

Authors:  Syed Parwez Hasan; Shahzad Hashmi; Mohammed Alhassen; William Lawson; Oswaldo Castro
Journal:  J Natl Med Assoc       Date:  2003-07       Impact factor: 1.798

8.  Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.

Authors:  S Charache; M L Terrin; R D Moore; G J Dover; F B Barton; S V Eckert; R P McMahon; D R Bonds
Journal:  N Engl J Med       Date:  1995-05-18       Impact factor: 91.245

9.  Patients with sickle cell disease have increased sensitivity to cold and heat.

Authors:  Amanda M Brandow; Cheryl L Stucky; Cheryl A Hillery; Raymond G Hoffmann; Julie A Panepinto
Journal:  Am J Hematol       Date:  2012-10-31       Impact factor: 10.047

10.  Quantitative sensory testing and pain-evoked cytokine reactivity: comparison of patients with sickle cell disease to healthy matched controls.

Authors:  Claudia M Campbell; C Patrick Carroll; Kasey Kiley; Dingfen Han; Carlton Haywood; Sophie Lanzkron; Lauren Swedberg; Robert R Edwards; Gayle G Page; Jennifer A Haythornthwaite
Journal:  Pain       Date:  2016-04       Impact factor: 7.926

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.